Serum level of fibroblast growth factor 23 in maintenance renal transplant patients | Zendy

Ana SánchezFructuoso | Zendy; M. L. Maestro | Zendy; Isabel Pérez-Flores | Zendy; Rosalía Valero | Zendy; S. Rafael | Zendy; S. Veganzones | Zendy; Natalia Calvo | Zendy; Virginia de la Orden | Zendy; José C. De La Flor | Zendy; Francisco Valga | Zendy; Marta Vidaurreta | Zendy; Cristina Fernández | Zendy; A. Barrientos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum level of fibroblast growth factor 23 in maintenance renal transplant patients

Author(s) -

Ana SánchezFructuoso,

M. L. Maestro,

Isabel Pérez-Flores,

Rosalía Valero,

S. Rafael,

S. Veganzones,

Natalia Calvo,

Virginia de la Orden,

José C. De La Flor,

Francisco Valga,

Marta Vidaurreta,

Cristina Fernández,

A. Barrientos

Publication year - 2012

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs409

Subject(s) - medicine , fibroblast growth factor 23 , renal transplant , fibroblast growth factor , transplantation , urology , parathyroid hormone , calcium , receptor

The discovery of fibroblast growth factor 23 (FGF23) provides a new conceptual framework that improves our understanding of the pathogenesis of post-transplant bone disease. Excess FGF23 is produced in the early post-transplant period; levels return to normal in the months following transplant. However, few manuscripts discuss FGF23 levels in stable long-term renal transplant recipients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research